A 42-year-old Indian male presents with recurrent myocardial infarction and prominent xanthomas on his Achilles tendons and knuckles. Lipid profile shows LDL cholesterol of 320 mg/dL despite atorvastatin 80 mg daily. The structure marked **C** in the diagram (LDL) is not being cleared effectively from the circulation. Genetic testing confirms a heterozygous mutation in the LDL receptor gene on chromosome 19. Which of the following therapeutic agents would be most effective in this patient by increasing the recycling and availability of LDL receptors on peripheral tissues?